CVS HEALTH CORPORATION— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$105.69B
↑+8.2% +$7.98Bvs FY2024 (Q4)
Gross Profit
$46.63B
↑+9.9% +$4.19Bvs FY2024 (Q4)
Operating Income
$2.11B
↓-10.8% -$256Mvs FY2024 (Q4)
Net Income
$1.35B
↓-17.6% -$290Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $105.69B | $97.71B |
| COGS | $59.06B | $55.27B |
| Gross Profit | $46.63B | $42.44B |
| R&D | $0 | $0 |
| SG&A | $0 | $0 |
| D&A | $1.15B | $1.15B |
| Other OpEx | $43.37B | $38.93B |
| Operating Income | $2.11B | $2.37B |
| Interest Exp. | $758M | $242M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $1.35B | $2.13B |
| Tax | $0 | $482M |
| Net Income | $1.35B | $1.64B |
QuarterCharts · SEC EDGAR data · CVS · Comparing FY2025 (Q4) vs FY2024 (Q4)